Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Britain Courts Anthropic Amid US Defense Department Dispute 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
NEW YORK, Oct. 05, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Seres Therapeutics, Inc. (NASDAQ:MCRB) securities between June 25, 2015 and July 29, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/seres-therapeutics-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Seres Therapeutics made materially false and misleading positive statements about the potential and efficacy of its lead drug product candidate SER-109. In particular, it is alleged that Seres touted the drug, calling it one among a “novel class of biological drugs” and a potential “first-in-field drug” despite knowledge that the Phase 2 clinical trial of SER-109 would fail to achieve its primary endpoint as compared to placebo.
On July 29, 2016, the Company issued a press release announcing that the Phase 2 clinical trial of SER-109 did not achieve its primary endpoint. In an earnings call, President and CEO Roger J. Pomerantz also revealed that certain undisclosed modifications had been made to the formulation of SER-109 prior to the trial. Following this news, shares of Seres Therapeutics fell from a close of $35.77 on July 28, 2016, to a close of just $9.73 on August 1, 2016.
If you suffered a loss in Seres Therapeutics you have until November 28, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/seres-therapeutics-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
